Shots:

• The P-III IMpower010 study involves assessing Tecentriq vs BSC- in 1-005 participants in a ratio (1:1) with stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant CT
• The study met its 1EPs showed improvement in DFS in PD-L1+ stage II-IIIA populations and ITT stage IB-IIIA populations NSCLC. The 2EP’s include OS in the overall study population- ITT Stage IB-IIIA NSCLC
• The findings will be submitted to US FDA and EUA and presented at an upcoming medical meeting. Tecentriq is approved in the US- EU- and other countries- either alone or in combination with targeted therapies and/or CT in multiple cancer indications

 ­ Ref: Roche | Image: Roche